MedTrace Logo

Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes

NCT07269197 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 67

Last updated 2025-12-08

No results posted yet for this study

Summary

Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition where fat builds up in the liver, is common in patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may help improve liver health, but their effects on liver stiffness and fat are not yet well understood. This study aims to clarify these effects.

Therefore, the aims of this study are:

1. Measurement of liver stiffness and liver steatosis using novel ultrasound-based methods before initiating SGLT2 inhibitor therapy and 6 months after starting therapy.
2. Assessment of blood biomarkers that may indicate liver injury, increased fat accumulation, and cellular dysfunction before initiating SGLT2 inhibitor therapy and 6 months after starting therapy.
3. Evaluation of the relationship between biomarkers and ultrasound findings before the introduction of SGLT2 inhibitors and 6 months after the start of therapy.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Diabetes Mellitus, Type 2

Interventions

DRUG

Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor

In patients with T2DM initiating therapy with a SGLT2 inhibitor, the effects on the liver have been assessed.

Sponsors & Collaborators

  • Josip Juraj Strossmayer University of Osijek

    lead OTHER

Principal Investigators

  • Martina Smolić, MD, PhD · Faculty of dental medicine and health Osijek, Josip Juraj Strossmayer University Osijek, 31000 Osijek, Croatia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-22
Primary Completion
2025-10-10
Completion
2025-10-10

Countries

  • Croatia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07269197 on ClinicalTrials.gov